Becton, Dickinson and Company (NYSE:BDX) Stock Holdings Raised by Twin City Private Wealth LLC

Twin City Private Wealth LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 377.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,508 shares of the medical instruments supplier’s stock after buying an additional 9,097 shares during the quarter. Becton, Dickinson and Company accounts for approximately 2.3% of Twin City Private Wealth LLC’s holdings, making the stock its 8th largest holding. Twin City Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $2,611,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Bank of Jackson Hole Trust purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $25,000. Sierra Ocean LLC purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $29,000. Picton Mahoney Asset Management raised its holdings in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares during the period. Hopwood Financial Services Inc. purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $39,000. Finally, Versant Capital Management Inc raised its holdings in shares of Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 73 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of the business’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the completion of the transaction, the executive vice president now owns 5,544 shares in the company, valued at approximately $1,311,211.44. The trade was a 9.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Richard Byrd sold 459 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the transaction, the executive vice president now owns 6,952 shares of the company’s stock, valued at $1,598,960. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,984 shares of company stock worth $1,147,865 in the last 90 days. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $230.63 on Monday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $66.22 billion, a price-to-earnings ratio of 38.31, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The business has a 50 day simple moving average of $232.58 and a 200-day simple moving average of $231.93.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has approved a share buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.80%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, March 5th. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Finally, Barclays lifted their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.